Source link : https://www.newshealth.biz/health-news/new-bispecific-shrinks-nrg1-fusion-positive-lung-pancreatic-tumors/
(MedPage Today) — Zenocutuzumab (Bizengri), a bispecific antibody against HER2 and HER3, showed efficacy in patients with advanced NRG1 fusion-positive cancers, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer, according to… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114096 Author : Publish date : 2025-02-05 22:00:00 Copyright for syndicated content belongs to the linked Source.
Author : News Health
Publish date : 2025-02-05 22:00:00
Copyright for syndicated content belongs to the linked Source.